Antrum Biotech
Translational diagnostics company developing and commercialising rapid host-biomarker based assays and related diagnostic platforms for tuberculosis and other infectious respiratory diseases. Activities include assay R&D (antibody isolation, immunoassay and platform development), clinical validation across African populations, laboratory services and scale-up for market deployment, with an emphasis on resource-limited settings.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Rapid host-biomarker immunoassay for extra-pulmonary TB
A clinically validated rapid immunoassay platform that detects host-response biomarkers in pleural, pericardial, ascitic and cerebrospinal fluids to aid diagnosis of extra-pulmonary TB with minimal sample preparation.
Rapid host-biomarker immunoassay for extra-pulmonary TB
A clinically validated rapid immunoassay platform that detects host-response biomarkers in pleural, pericardial, ascitic and cerebrospinal fluids to aid diagnosis of extra-pulmonary TB with minimal sample preparation.
Services
Analysis of critical project aspects to determine probability of market success and technical feasibility.
Tissue culture and affinity chromatography workflows for isolation, purification and custom modification of antibodies for diagnostics.
R&D capability for developing novel immunoassays, specialising in ELISA and lateral flow formats and related platform optimization.
Analytical refinement and validation services to improve sensitivity, specificity and reproducibility of diagnostic platforms.
Process development and scale-up support for diagnostic immunoassay production.
High-quality clinical sample processing, on-site biorepository and sample logistics to support clinical trials.
Analysis of critical project aspects to determine probability of market success and technical feasibility.
Tissue culture and affinity chromatography workflows for isolation, purification and custom modification of antibodies for diagnostics.
R&D capability for developing novel immunoassays, specialising in ELISA and lateral flow formats and related platform optimization.
Analytical refinement and validation services to improve sensitivity, specificity and reproducibility of diagnostic platforms.
Process development and scale-up support for diagnostic immunoassay production.
High-quality clinical sample processing, on-site biorepository and sample logistics to support clinical trials.
Expertise Areas
- Diagnostic platform development
- Immunoassay development (ELISA, lateral flow, immuno-suspension)
- Host-biomarker discovery and deployment
- Clinical study execution and sample management
Key Technologies
- Immunoassays (ELISA, lateral flow, immuno-suspension)
- Electrochemical immunoassay platforms
- Affinity chromatography for antibody purification
- Tissue culture for antibody production
News & Updates
Report on development of a rapid test for tuberculosis meningitis that yields results within hours and is undergoing validation studies in southern Africa.
Announcement describing a rapid immunoassay platform for diagnosis of extra-pulmonary tuberculosis and its clinical validation in multiple African countries.
Summary of a cost-effectiveness analysis indicating that host-biomarker assays can offer good value compared to existing ADA testing for pleural tuberculosis diagnosis.
Overview of a study comparing nucleic-acid tests and host-biomarker assays in pleural fluid; reports higher sensitivity and rule-in value for host-biomarker assays in a high-burden, HIV-endemic setting.
Recognition noted for a spin-out diagnostic company for a rapid TB test that provides same-day results.
University news article reporting on a new rapid TB meningitis diagnostic and its potential impact.
Report on development of a rapid test for tuberculosis meningitis that yields results within hours and is undergoing validation studies in southern Africa.
Announcement describing a rapid immunoassay platform for diagnosis of extra-pulmonary tuberculosis and its clinical validation in multiple African countries.
Summary of a cost-effectiveness analysis indicating that host-biomarker assays can offer good value compared to existing ADA testing for pleural tuberculosis diagnosis.
Overview of a study comparing nucleic-acid tests and host-biomarker assays in pleural fluid; reports higher sensitivity and rule-in value for host-biomarker assays in a high-burden, HIV-endemic setting.
Recognition noted for a spin-out diagnostic company for a rapid TB test that provides same-day results.
University news article reporting on a new rapid TB meningitis diagnostic and its potential impact.